Fakultni Nemocnice Ostrava

Research site

Czechia 17. Listopadu 1790/5, 708 00 Poruba, Czechia

9 trials recruiting
Plasma cell myeloma · Chronic lymphocytic leukaemia · Magnetic resonance imaging
Adults and children

About Specializations

Fakultni Nemocnice Ostrava in Poruba, Czechia specialises in clinical trials of conditions such as Plasma cell myeloma, Chronic lymphocytic leukaemia, Magnetic resonance imaging, Dermatitis atopic, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

17. Listopadu 1790/5708 00 PorubaCzechia

Open in maps ↗

Recruiting now: 9 trials
Conditions studied: 55

More sites in Poruba Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

65 clinical trials

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study on Tinlarebant for Treating Geographic Atrophy in Patients

Investigational

Study on Tinlarebant for Treating Geographic Atrophy in Patients

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Tinlarebant
Sponsor:Belite Bio Inc.

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Oxaliplatin
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Registered drugNo placebo

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Teriflunomide
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Novartis Pharma AG

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Study on Optimizing Treatment for Chronic Heart Failure with Reduced Ejection Fraction Using Nebivolol and a Drug Combination

Registered drugNo placebo

Study on Optimizing Treatment for Chronic Heart Failure with Reduced Ejection Fraction Using Nebivolol and a Drug Combination

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bisoprolol Fumarate
Sponsor:Fakultni Nemocnice Ostrava

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Janssen Cilag International

Contact Research Centre

Plasma cell myeloma

Recruiting

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Celgene Corp.

Contact Research Centre

Nervous system disorder

Not yet recruiting

Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination

Registered drugNo placebo

Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Magnetic resonance imaging

Not yet recruiting

Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

InvestigationalNo placebo

Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

InvestigationalNo placebo

Czechia

Participants:0–17 years
Substances:Gadoquatrane
Sponsor:Bayer AG

Contact Research Centre

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Rocatinlimab
Sponsor:Amgen Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites